Prescient is an evidence-based decision-support partner to the pharmaceutical and biotech industries whose mission is to optimally shape new product, brand and mature product planning strategies.

Our diverse yet integrated skillsets and methodologies ensure our clients’ key decisions are objectively assessed from both a clinical and commercial perspective, resulting in differentiated products and offerings.


Shaping Decisions Driving Value

Our People

Prescient’s team consists of highly experienced executives who share our core values of thinking collaboratively, creatively and constructively. We effectively integrate different skills and perspectives into a single client-engagement team.

Our Approach

The format and scope of our engagements are customized to meet our clients’ needs and our ‘best-in-front’ team philosophy ensures access to the necessary levels of expertise and thinking.

Our Clients

We engage directly with a number of functions supporting new product, brand and mature product planning activities; to view a full list of these, please click the
link below.

Latest News

Pfizer completes acquisition of Anacor

Nanotechnology and math deliver two-in-one punch for cancer therapy resistance

Amgen Golden Ticket winners receive lab space and other benefits at QB3@953

More reasons to eat your broccoli

Help Pfizer change the future of healthy aging vs. Drugs@FDA: A comparison of results reporting for new drug trials

Merck Family Foundation established

Roche employees raise funds for vulnerable children in over 90 communities around the world

Natural molecule could improve Parkinson's

Sanofi announces expiration of Hart-Scott-Rodino waiting period regarding proposed acquisition of Me …

New drug clears psoriasis in clinical trials

Novartis expands partnership with Medicines for Malaria Venture to develop next-generation antimalar …

Probing proteins' 3-D structures suggests existing drugs may work for many cancers

Merck in agreement with HAPPYneuron to offer first-of-its kind e-Health solution for people living w …

FDA targets unlawful internet sales of illegal prescription medicines during International Operation …

Cancer immunotherapy may increase risk of developing rheumatologic disorders: Johns Hopkins study

MolMed gains European conditional nod for ‘suicide gene’ drug

Chutes & Ladders: Valeant names Sam Eldessouky its accounting head

CRISPR Therapeutics adds $38M to Series B pot, but lags behind Parker

Medivation slams Sanofi’s ‘misleading’ claims as merger saga continues

Uncertainty for biotech as U.K. exits EU, prime minister to resign

Hengrui Therapeutics gains $100M investment to further cancer pipeline

Slow death of Eleven Bio continues as 70% of staff axed

Greg Doyle takes top job at Leading BioSciences as Straw moves aside

Epizyme nabs combo trial deal with Genentech for NHL candidate

EuroBiotech Report: A-list backers pump £45M into COPD player with Nasdaq aspirations

NEA leads $44M round to get Stanford neurodegenerative spinout Annexon into the clinic

Incyte shrugs off trial failures with Merck PD-1/epacadostat tie-up

Kelly Martin’s Malin secures €70M to invest in EU biotechs

Woodford upped his stake in Circassia days before trial flop

Natsimbio may become sole supplier of blood-plasma and other drugs to Russian government

EMA reviews Pharmaceutics International’s alleged cross-contamination and quality breaches

UK pharma and biotech industries concerned at Brexit vote

R&D growth and new blockbusters predicted by report

ICER report finds Ocaliva an important advance, but too expensive

US lawmakers introduce legislation to reduce biologics prices, cut exclusivity period

Medivation urges shareholders to fight off Sanofi takeover

ABPI suspends Astellas from membership of the trade group

UK votes to leave European Union – now what?

Teva and AstraZeneca reach patent settlement on Byetta

India dumps 2013 Bill as government creates new drugs regs

FDA Breakthrough designation for Incyte’s Jakafi in acute GVHD

Zhejiang Hisun to market Fujifilm’s anti-influenza drug in China

Gilead’s Odefsey gains EU approval

Newron Pharma key value driver is Xadago, says ValuationLAB

Medical News Today: Scientists offer new view on origins of Parkinson's disease

Medical News Today: Cancer breakthrough? Novel insight into metastasis could offer new treatments

Medical News Today: Study characterizes older adults who may need help managing medications

Medical News Today: How Does Coffee Affect Diabetes?

Medical News Today: Signs and Symptoms of Diabetes in Men

Medical News Today: Virtual heart reveals new clues to heart failure

Medical News Today: Memory improved by protein released in response to running

Medical News Today: Could hops extract reduce risk of breast cancer?

Medical News Today: Heart attack death increased by more than 50 percent for diabetes patients

Medical News Today: HIV entry mechanism into immune cell nucleus revealed

Medical News Today: How Should I Organize my Diet to Help my Diabetes?

Medical News Today: 10 Exercises for Arthritis of the Knee

Medical News Today: Huntington's risk genes '10 times more common than previously thought …

Medical News Today: New head-scanning ultrasound technology could help diagnose brain injuries

Medical News Today: Heart disease seen as a man's issue by many male doctors

EU nod for Gilead’s single-pill HIV therapy

NICE sticks with decision to reject Celgene’s Vidaza

US recommends against use of AZ’ flu jab

Trulicity gets seal of approval for Welsh NHS

Great Britain votes to separate from European Union

Communications Team of the Year 2016 – open for entries

Final NICE nod for GSK’s lupus drug Benlysta

NHS Alliance calls for pharmacy ‘forward view’

Timely use of Novartis’ Entresto could save thousands of lives

UK pharma reiterates its ‘Remain’ plea

Five new medicines make it onto the NHS

FDA to review Mitsubishi’s ALS drug

EU regulators review Santhera’s Raxone for Duchenne

Alzheimer’s can cause diabetes, study finds

Takeda kicks off world’s first norovirus vaccine field trial

More News